Elsevier,
IBRO Neuroscience Reports, Volume 16, June 2024
This article summarizes current biomarkers, available treatments, and future therapeutic approaches for Alzheimer's disease, discussing drug targets like Amyloid β, Tau Protein, and various other mechanisms. Additionally, it highlights the historical use of Estradiol, outcomes of trials with antioxidants and omega-3 fatty acids, and ongoing clinical trials, providing a comprehensive overview of the evolving landscape in AD research and treatment.
Elsevier,
Neurochemistry International, Volume 176, June 2024
This study finds that impaired cellular immune dysfunction in AD patients was significantly correlated with abnormal MRS, and neuroimmune dysfunction may contribute to the pathogenesis of AD and alter the metabolism of neurotransmitters such as aspartic acid and MI in the brains of AD patients.
Elsevier,
Journal of Neuroscience Methods, Volume 406, June 2024
This study presents an optimized method for isolating specific neuronal and glial cell populations and extracellular vesicles (EVs) from postmortem Alzheimer's disease (AD) cortical samples, demonstrating the feasibility of using a single cryopreserved brain sample to obtain RNA-seq and protein-level data, thereby enhancing understanding of neuron/glial interactions and disease progression.
Elsevier,
Brain Research Bulletin, Volume 212, 15 June 2024
This study reveals that Dl-3-n-butylphthalide (NBP) improves learning deficits and reduces Aβ plaque deposition in Alzheimer's disease (AD) transgenic mice by enhancing microglial activation and phagocytosis of Aβ plaques. The therapeutic effects of NBP are linked to the AGE-RAGE signaling pathway, demonstrating its potential in alleviating cognitive impairment and neuroinflammation in AD.
Elsevier,
Brain Research, Volume 1832, June 2024
Recent research on Alzheimer's disease (AD) suggests that microglia, immune cells in the brain, may play a beneficial role in early disease stages but become harmful in later stages due to various spatial, temporal, and transcriptional factors. Understanding the phenotypic heterogeneity and multiple states of microglia could lead to advancements in personalized medicine and improved treatment outcomes for AD patients.
Elsevier,
Molecular and Cellular Neuroscience, Volume 129, June 2024
Neurological disorders affect approximately one billion people worldwide, with significant disability and mortality impacts, and this review explores how Heparan sulfate proteoglycans (HSPGs) promote Tau fibril formation and tangles in Alzheimer's disease, and the potential role of tunnelling nanotubes (TNTs) in the intercellular transport of Tau and Amyloid β proteins, suggesting that HSPGs may influence TNT formation in neurodegenerative conditions.
Elsevier,
Mechanisms of Ageing and Development, Volume 219, June 2024
This study identified key biochemical pathways and protein changes in the Alzheimer's disease (AD) human hippocampus, revealing increased expression of proteins VGF, GFAP, HSPB1, and APP, with UBC being most centrally involved, and highlighted the roles of four hub proteins (CD44, APP, ITGB2, APOE) linked to amyloid plaques and two (RPL24, RPS23) to neurofibrillary tangles, along with the impact of modified proteins on immune activation and synaptic disruption, uncovering potential therapeutic targets involving specific proteins, microRNAs, and transcription factors.
Elsevier,
eClinicalMedicine, Volume 72, June 2024
This Article supports SDG3 by evaluating sex and gender disparities in terms of risk factors, treatment uptake/completion, and virological outcomes for hepatitis C, finding differences between men and women in, for example, exposure to different risk factors and likelihood of commencing treatment. More attention is needed in research to these disparities and how they could be addressed
